Krystal Biotech, Inc. (KRYS) — Fair Value Analysis
Base-case fair value (P50): $343.35 · Current price: $371.56 · Verdict: Fairly Valued
The Verdict on KRYS
KRYSTAL BIOTECH INC (KRYS) is currently assessed as Fairly Valued by our Monte Carlo simulations. The median fair value (P50) for KRYS stands at $343.35, closely aligned with its current market price of $371.56. This valuation suggests an -7.6% when compared to its current trading level, indicating that the market largely reflects the company's intrinsic value as determined by our forward-looking model. While the current price is slightly above the median fair value, it falls within the range our simulations deem appropriate for a 'Fairly Valued' assessment, rather than signaling it as significantly overvalued.
How KRYS stacks up against peers
When evaluating KRYSTAL BIOTECH INC (KRYS) within its operational landscape, the company holds an 'average' quality tier, reflecting its balanced operational and financial health relative to peers. This average quality tier supports the Monte Carlo simulation's 'Fairly Valued' verdict. Despite a minor -7.6% relative to the median fair value of $343.35 from its $371.56, the average quality profile suggests the current valuation is reasonable, balancing potential growth against existing risks. Our comprehensive simulations incorporate these fundamental strengths and weaknesses to provide a nuanced fair value assessment for a company in this space.
What this means for investors
For investors considering KRYS, the Monte Carlo analysis suggests that at $371.56, the stock is priced close to its median fair value of $343.35. The -7.6% indicates a relatively balanced outlook for the stock. Given its 'average' quality tier, the current market pricing seems justified, making it neither a strong buy nor a strong sell purely based on current valuation. To fully understand KRYS's risk-reward spectrum, including detailed bear and bull case scenarios, sign up for a free FairCurve account and track KRYS's fair value as new fundamentals are released.
Frequently Asked Questions
Is KRYS overvalued or undervalued right now?
Based on our Monte Carlo simulations, KRYSTAL BIOTECH INC (KRYS) has a median fair value (P50) of $343.35. With a current price of $371.56, KRYS is assessed as Fairly Valued.
What is the bear case and bull case for KRYS?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is available exclusively to FairCurve account holders. These detailed scenarios are crucial for understanding the complete risk and reward spectrum for KRYS.
How does FairCurve calculate KRYS's fair value?
FairCurve determines KRYS's fair value through advanced Monte Carlo simulations, running thousands of forward-looking financial scenarios. This robust methodology captures a wide range of potential outcomes to provide a probabilistic distribution of intrinsic value.
How can I track KRYS's fair value as it changes?
You can add KRYSTAL BIOTECH INC (KRYS) to a free FairCurve watchlist for daily fair value updates. This ensures you receive instant re-valuation notifications whenever new financial data, such as earnings reports, is released.